What Is the Success Rate of BCG Treatment for Bladder Cancer?

BCG treatment prevents or delays bladder cancer recurrence in roughly 60 to 70 percent of patients with non-muscle-invasive disease over the first several years, though those numbers shift considerably depending on how completely the treatment course is delivered, the specific BCG strain used, and the risk profile of the tumor. That range makes BCG one of the most effective intravesical therapies available, but it also means a meaningful minority of patients will see their cancer return. Understanding why success rates vary so widely, and what happens when BCG does not work, matters for anyone navigating this treatment.

How BCG Works Inside the Bladder

BCG is a live but weakened form of a bacterium related to the one that causes tuberculosis. When instilled directly into the bladder through a catheter, it does not kill cancer cells the way chemotherapy does. Instead, it triggers an immune response. Both the innate immune system (the body’s first-line defenders) and the adaptive immune system (the longer-term, targeted response) get activated, eventually leading to destruction of residual tumor cells.¹ Research in animal models shows that BCG causes a large, temporary surge of immune cells into the bladder lining, particularly CD4+ T cells, and that this recruitment is more pronounced than what intravesical chemotherapy produces.² The treatment essentially reprograms the bladder’s local environment into one that is hostile to cancer, which is why its effects can persist well beyond the treatment period itself.

What the Numbers Look Like Over Time

The headline success rate depends on what you measure and how long you follow patients. A single-center study tracking patients over five years found relapse-free survival of about 61 percent, progression-free survival near 86 percent, and overall survival of 93 percent.³ An Australian retrospective study reported a one-year disease-free survival of 72 percent, dropping to 41 percent at five years.⁴ A randomized trial looking at maintenance schedules found disease relapse at five years of roughly 34 to 39 percent, depending on the maintenance arm.⁵

These figures might seem inconsistent, but they reflect differences in patient populations, tumor grades, follow-up periods, and how “success” is defined. Recurrence (cancer comes back at the same or a lower stage) is far more common than progression (cancer advances to invade the muscle wall), and overall survival remains high because even patients who recur can often be treated again successfully. The critical distinction for most patients is between recurrence and progression, since progression to muscle-invasive disease dramatically changes the treatment landscape.

Why Completing the Full Course Matters

One of the clearest predictors of BCG success is whether a patient receives an adequate course of treatment. A 2025 comparative analysis found that patients who received adequate BCG had a five-year recurrence-free survival of 72 percent, versus 52 percent for those who received an inadequate course. Progression-free survival was 92 percent in the adequate group versus 85 percent, and overall survival was 88 percent versus 71 percent.⁶ That gap is striking. Patients who get shortchanged on treatment, whether because of side effects, supply issues, or scheduling problems, face substantially worse outcomes.

This finding has practical implications beyond individual decision-making. A comparison of optimal mitomycin C chemotherapy versus nonoptimal BCG found that patients who received a complete course of the chemotherapy drug actually had better four-year recurrence-free survival (about 82 percent) than those receiving an incomplete BCG course (65 to 68 percent).⁷ In other words, BCG’s superiority over alternative intravesical agents holds only when the full treatment regimen can be delivered. An incomplete BCG course can be worse than a completed course of a less potent drug.

BCG Versus Intravesical Chemotherapy

BCG’s main competitor for intravesical treatment is mitomycin C, a chemotherapy drug instilled directly into the bladder. A Cochrane systematic review comparing the two found that BCG may slightly reduce the time to recurrence compared to mitomycin C, but made little or no difference in time to progression or overall survival. BCG did appear to carry a higher risk of serious side effects.⁸ The evidence quality across those comparisons was rated low, meaning the true difference could be larger or smaller than what the data show.

The practical takeaway is that for high-risk non-muscle-invasive bladder cancer, BCG remains the standard of care because of its superior recurrence prevention. For intermediate-risk tumors, the choice is more nuanced, and mitomycin C becomes a reasonable option, particularly if a patient cannot tolerate BCG side effects or if supply constraints make a full BCG course unlikely.

The Strain You Get Can Affect Results

Not all BCG is the same. Different manufacturing strains (most commonly Connaught and Tice) come from the same original bacterial culture but have diverged over decades of separate laboratory propagation. This turns out to matter clinically. One study found that five-year recurrence-free survival with the Connaught strain was 74 percent, compared to 48 percent with the Tice strain.⁹

However, the story is more complicated than “one strain is better.” A large cohort study of over 2,000 patients with aggressive T1 high-grade disease found that the strains performed differently depending on whether maintenance therapy was given. Without maintenance, Connaught delayed recurrence more effectively. With maintenance, Tice was actually more effective at preventing recurrence and showed a trend toward better cancer-specific survival. For progression and overall survival, the two strains performed similarly.¹⁰ Most patients do not get to choose their strain, since supply dictates what is available, but this interaction between strain and maintenance schedule is something clinicians consider when designing treatment plans.

Dose Reduction and Side Effect Trade-offs

Because BCG side effects drive many patients to quit treatment early, researchers have studied whether a lower dose could preserve cancer control while reducing toxicity. A systematic review and meta-analysis found that reduced-dose BCG led to meaningfully fewer side effects, with local adverse events dropping by about 19 percent and systemic adverse events roughly halving compared to the full dose. Cancer outcomes (recurrence and progression) showed a slight trend toward being worse with lower doses, but the differences were not large enough to be statistically definitive.¹¹

A network meta-analysis came to a similar conclusion: standard-dose BCG caused nearly double the adverse events compared to reduced-dose, and standard-dose BCG is still preferred for intermediate- and high-risk patients based on cancer control. But for patients who develop serious side effects or when full-dose BCG is unavailable, a reduced dose or intravesical chemotherapy (particularly gemcitabine) is considered a reasonable alternative.¹²

When BCG Is Considered to Have Failed

Defining BCG failure is not as straightforward as it might seem. A widely used data-driven definition considers a patient “BCG unresponsive” if cancer persists or recurs after two courses of BCG, specifically multifocal papillary tumors within six months or carcinoma in situ within 12 months of the last BCG course.¹³ This definition matters because it determines eligibility for clinical trials and newer therapies.

In practice, though, many patients fall through the cracks of these criteria. Maintenance BCG is often not delivered as planned, surveillance schedules vary between institutions, and key tumor details needed for classification are frequently missing from medical records. A 2025 analysis found that a substantial proportion of patients cannot be reliably classified as BCG-unresponsive under existing definitions, not because of their tumor biology, but because the structural assumptions in the definitions do not match how care actually plays out in everyday clinical settings.¹⁴ This mismatch is a real problem because patients whose BCG has clearly failed may be shut out of newer treatment options simply because their records do not tick every box in a regulatory definition.

Options After BCG Failure

For patients whose cancer returns after BCG, radical cystectomy (surgical removal of the bladder) has traditionally been the recommended next step. A UK study found that event-free survival was significantly longer for patients who underwent cystectomy compared to bladder-sparing treatment: about 70 months versus 26 months. However, three- and five-year cancer-specific survival and overall survival did not differ significantly between the two groups.¹⁵ This suggests that bladder-sparing approaches may be reasonable for selected patients, though the question of whether delaying cystectomy worsens long-term outcomes remains debated.

The landscape of bladder-sparing salvage therapies has expanded rapidly. Immune checkpoint inhibitors like pembrolizumab have achieved complete response rates of about 41 percent in carcinoma in situ patients after BCG failure. Gene therapies such as nadofaragene firadenovec have reached 51 percent complete response rates, and the combination of an IL-15 agent (Anktiva) with BCG recently gained FDA approval after showing a 71 percent complete response rate with a median duration of nearly 27 months.¹⁶ A phase I/II trial of BH011, another investigational agent, reported a 96 percent complete response rate at three months and 71 percent at 12 months in BCG-failure patients, though the study was small.¹⁷ Hyperthermic intravesical chemotherapy with gemcitabine and docetaxel has also shown promise, with one study reporting a treatment success rate of about 74 percent at one year and 56 percent at two years in BCG-failure patients.¹⁸

These numbers represent a genuine shift. A decade ago, BCG failure meant choosing between cystectomy and relatively ineffective alternatives. Patients now have multiple bladder-preserving options with meaningful response rates, though none is a guaranteed cure and long-term data for many of these agents is still maturing.

Side Effects and Treatment Compliance

BCG’s side effects are a practical barrier to completing treatment. In a retrospective study of 276 patients, about 8 percent developed clinically relevant local or systemic side effects. The most common local issue was cystitis-like symptoms (urgency, burning, frequency), affecting about 78 percent of those who had any side effect. Systemic reactions included fatigue and fever, with high fever lasting more than 48 hours occurring in fewer than 9 percent of affected patients.¹⁹ Those numbers make BCG sound manageable, but the day-to-day reality is more cumulative: mild urinary symptoms build up over weeks of treatment and can significantly affect daily life.

Discontinuation rates vary widely depending on how side effects are managed. One study comparing different management strategies found that proactive approaches to functional impairment brought discontinuation rates down to about 9 to 12 percent, compared to 35 percent in patients managed with standard care alone.²⁰ BCG toxicity is not the only reason patients stop early; supply shortages have also become a leading cause of treatment interruption.²¹

The BCG Supply Crisis

BCG production is concentrated among a handful of manufacturers worldwide, and supply disruptions have been recurring for over a decade. This is not a minor logistical headache. When the Connaught strain became unavailable and patients were switched to alternative protocols, one study documented a 24-month recurrence rate of about 47 percent in the shortage-affected group compared to 16 percent in the pre-shortage control group.²² Multiple studies from Spain have confirmed that BCG shortages and the resulting reduced-dose regimens increase early tumor relapse rates.²³²⁴

Supply shortages effectively force clinicians into a position where they know the treatment they are delivering is suboptimal. Some patients receive reduced doses, others have extended gaps between instillations, and some are switched to alternative agents entirely. All of these compromises erode the success rates that BCG achieves under ideal conditions. If you are starting BCG treatment, it is worth asking your care team whether they have a reliable supply for the full planned course.

Predicting Who Will Respond

Existing risk-stratification tools, such as the EORTC and CUETO scoring systems, provide recurrence and progression probability scores for non-muscle-invasive bladder cancer patients. However, these tables tend to overestimate risk for high-risk patients treated with BCG, and researchers are working to improve predictions using tumor substaging, tumor budding patterns, and artificial intelligence analysis of tissue samples.²⁵

On the biomarker front, single markers like tumor p53 expression have shown limited ability to predict BCG response, likely because the immune reaction BCG generates is too complex to capture with one measurement. Broader panels of urinary cytokines have performed better.²⁶ One study found that changes in specific urinary cytokine levels at around 13 weeks into treatment could help predict which patients were more likely to fail BCG, and that smoking status was independently associated with response.²⁷ None of these approaches is ready for routine clinical use yet, but the direction of the research is toward personalized treatment decisions rather than one-size-fits-all BCG protocols.

Quality of Life During and After Treatment

Success rates measured in tumor recurrence and survival tell only part of the story. A systematic review of quality-of-life studies found that patients undergoing intravesical instillations commonly reported urinary symptoms, fatigue, and emotional distress, and that frequent hospital visits and the time commitment involved were major complaints. In one included study, 60 percent of patients who discontinued treatment cited persistent mild discomfort affecting their social life, and the severity of side effects did not always predict treatment effectiveness.²⁸

A prospective study using a bladder-cancer-specific quality-of-life questionnaire found an interesting split: physical well-being scores worsened during BCG treatment, but emotional well-being actually improved, likely because patients felt reassured by actively treating their cancer. Patients over 75 showed statistically significant emotional improvement, while younger patients experienced more pronounced declines in physical and bladder-specific quality of life.²⁹ A U.S. survey of patients receiving intravesical treatment found high symptom burden and substantial work impairment, with employed participants reporting roughly 50 percent work impairment during treatment.³⁰

These quality-of-life findings matter because BCG treatment is not a one-time event. A full course typically involves six weekly instillations followed by maintenance cycles that can stretch over one to three years. The treatment is effective, but it demands sustained commitment from patients who are simultaneously dealing with cancer-related anxiety and physical discomfort. Asking your care team about strategies to manage side effects proactively, rather than waiting until they become intolerable, can make a meaningful difference in whether you complete the course and get the full benefit.